Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 111,300 shares, a decline of 23.5% from the June 30th total of 145,400 shares. Approximately 5.4% of the company’s stock are short sold. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 0.1 days.
Analyst Ratings Changes
BPTH has been the topic of several analyst reports. Roth Mkm restated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th. StockNews.com started coverage on shares of Bio-Path in a report on Thursday, May 2nd. They set a “sell” rating on the stock.
Read Our Latest Stock Analysis on Bio-Path
Bio-Path Stock Performance
Bio-Path (NASDAQ:BPTH – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.54) by ($0.34). Analysts forecast that Bio-Path will post -5.53 earnings per share for the current year.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- What is Put Option Volume?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Find Undervalued Stocks
- Why Call Options Volume for These 2 Stocks Spiked Together
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.